← Back to IPO List

SpyGlass Pharma

Last updated: February 6, 2026
Ticker
SGP
Exchange
NYSE
IPO Date
Pending
Price Range
$15.00 - $17.00
Deal Size
$150 million
View SGP Live Chart on TradingViewAffiliate link — we may earn a commission.

Company Snapshot

SpyGlass Pharma is a late-stage biopharmaceutical company focused on transforming the treatment of chronic eye conditions through long-acting, sustained drug delivery systems. The company aims to improve patient outcomes by developing innovative solutions that reduce the need for daily medication. Its lead product, the Bimatoprost Drug Pad-IOL System, is designed to be implanted during cataract surgery to manage elevated intraocular pressure in glaucoma patients. SpyGlass Pharma is committed to enhancing the quality of life for patients with chronic eye conditions.

Key Financials

Metric202420232022
RevenueNot providedNot providedNot provided
Adjusted Net Loss-$29.2M-$13.3MNot provided

S-1 Highlights

Market & Competition

The company operates in the biopharmaceutical market and competes with established players in the glaucoma treatment space. Specific competitors are not mentioned in the filing.

Use of Proceeds

The company plans to use the proceeds from the IPO to fund research and development activities, operational expenses, and to support the advancement of its product candidates.

Key Risk Factors

  • ●The company faces significant risks related to its ability to obtain regulatory approval for its drug candidates, which could adversely affect its financial position and operations.
  • ●The company may not be able to secure additional funding on acceptable terms, which could hinder its ability to continue operations and develop its products.

Reported Broker Availability

No broker information available yet

Check back later for updates

Reported by users or publicly disclosed. Information is for reference only.

Important Links & Filings

SGP Live Chart on TradingView →SEC S-1 Filing →
Important: Information presented on this website is aggregated from publicly available sources and voluntary user submissions. It is provided for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. IPO access and availability may vary by broker and is not guaranteed; always verify details directly with your broker before making any investment decisions. We are not affiliated with, endorsed by, or acting on behalf of any broker-dealers, underwriters, or issuing companies. Some links to broker platforms may be affiliate links, and we may earn a commission if you open an account through those links. See full disclaimer for additional information.